Evok stock zacks
EVOK is currently trading at $2.67 per share and is down 9.83% as of Jan. 9 YOY. Crowdsourced stock and analyst ratings and analysis for GlycoMimetics, Inc. ($GLYC) from the leading crowdsourced stock rating platform. Evoke Pharma (EVOK) Given a $9.00 Price Target by HC Wainwright Analysts (americanbankingnews.com) Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA (zacks.com) FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women (empr… For stock investors, the falling rates environment is now favoring one particular sector: consumer staples. Coeur Mining Inc (NYSE:CDE) SVP Hans John Rasmussen sold 7,500 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $4.78, for a total value of $35,850.00.
We are now in a quiet stretch for earnings reports, but investors can still use the Zacks Earnings Calendar to prepare for important dates from companies with abnormal fiscal periods.
Get today's Evoke Pharma Inc stock price and latest EVOK news as well as Evoke Pharma real-time stock By Zacks Investment Research - May 07, 2019. Technical stock forecast for EVOK: Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a Stock split history for Evoke Pharma since 2020. Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal Fundamental data from Zacks Investment Research, Inc. Real-time trade and investing ideas on Evoke Pharma EVOK from the largest community of traders and investors. 29 Nov 2019 Get breaking news and analysis on Evoke Pharma, Inc. (EVOK) stock, price quote and chart, trading and at Zacks.com (May 8, 2019).
7/11/2016 · AMPHASTAR PHARM (AMPH): Free Stock Analysis Report. EVOKE PHARMA (EVOK): Free Stock Analysis Report. To read this article on Zacks.com click here. Zacks Investment Research. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
Crowdsourced stock and analyst ratings and analysis for Progenics Pharmaceuticals Inc. ($PGNX) from the leading crowdsourced stock rating platform.
1 day ago Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to
8/17/2018 · Zacks Rank & Key Picks. Evoke currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the pharma space are Illumina ILMN and Ligand Pharmaceuticals LGND. Both the stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
27 Dec 2019 The stock was purchased at an average cost of $4.75 per share, for a total missing the Zacks' consensus estimate of ($2.10) by ($0.10). 1 day ago Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to 27 Dec 2019 HC Wainwright reiterated a “hold” rating on shares of Evoke Pharma in a research report on Monday, December 2nd. Zacks Investment 1 day ago Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to
View Evoke Pharma, Inc. EVOK investment & stock information. Get the latest Evoke Pharma, Inc. EVOK detailed stock quotes, stock data, Real-Time ECN, EVOK: Evoke Pharma, Inc. broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research. Find the latest Evoke Pharma, Inc. (EVOK) stock quote, history, news and other vital information to help you with your stock trading and Zacks•3 months ago Find the latest Earnings Report Date for Evoke Pharma, Inc. Common Stock (EVOK) at Our vendor, Zacks Investment Research, hasn't provided us with the Evoke Pharma stocks price quote with latest real-time prices, charts, Evoke Pharma (EVOK). Zacks Equity Research - ZACKS - Fri Sep 20, 4:14PM CDT. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat EVOK | Complete Evoke Pharma Inc. stock news by MarketWatch. View real-time stock prices and Stock Down. Sep. 19, 2019 at 10:29 a.m. ET on Zacks.com